<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02334722</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201400876</org_study_id>
    <secondary_id>OCR14673</secondary_id>
    <nct_id>NCT02334722</nct_id>
  </id_info>
  <brief_title>1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients</brief_title>
  <official_title>A Shortened Antiepileptic Drug (AED) Course in Surgical Brain Tumor Patients: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if there are any differences in patient reported&#xD;
      neurotoxicity between patients who receive Levetiracetam tablets for one week after surgery&#xD;
      to remove a brain tumor versus those who receive Levetiracetam tablets for six weeks after&#xD;
      surgery. Specifically, we will see if one group has less side effects than the other, and&#xD;
      whether or not one group has more seizures than the other.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Because seizures are one of the leading neurologic complications in brain tumor patients,&#xD;
      neurosurgeons prescribe antiepileptic drugs (AEDs) to help prevent them. Although the&#xD;
      American Academy of Neurology (AAN) guidelines recommend that AEDs be stopped after the first&#xD;
      post-operative week in patients without seizures, there is no standard length of treatment&#xD;
      and some patients may stay on AEDs indefinitely.&#xD;
&#xD;
      In an attempt to develop clinical guidelines for AED use in post-operative brain tumor&#xD;
      patients, we will try to determine if taking levetiracetam for 1 week results in less&#xD;
      neurotoxicity than taking it for 6 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 5, 2015</start_date>
  <completion_date type="Actual">October 7, 2020</completion_date>
  <primary_completion_date type="Actual">October 7, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Neurotoxicity Scale Scores</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>The Neurotoxicity Scale is as a validated 24 question, patient-reported measure for assessing the adverse effects of antiepileptic drugs on cognitive function. Patients self-report &quot;no problem&quot;, &quot;a mild problem&quot;, &quot;a moderate problem&quot; or &quot;a serious problem&quot; for each question corresponding to a score of 0, 1, 2, and 3.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Brain Neoplasms</condition>
  <condition>Brain Cancer</condition>
  <condition>Brain Tumors</condition>
  <condition>Cancer of the Brain</condition>
  <condition>Cancer of Brain</condition>
  <condition>Seizure</condition>
  <arm_group>
    <arm_group_label>1 Week Levetiracetam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levetiracetam taken by mouth at a daily dose of 1000 mg for one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 Week Levetiracetam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levetiracetam taken by mouth at a daily dose of 1000 mg for six weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <arm_group_label>1 Week Levetiracetam</arm_group_label>
    <arm_group_label>6 Week Levetiracetam</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (&gt;18 years of age and older) patients who have or will have undergone surgical&#xD;
             resection or biopsy of a supratentorial brain tumor and are able to consent for&#xD;
             themselves.&#xD;
&#xD;
          -  Able to be randomized prior to or up to 48 hours after surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No known history of seizure activity.&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  Renal dysfunction (CrCl &lt; 30ml/min).&#xD;
&#xD;
          -  Beck's Depression Inventory (BDI) â‰¥14&#xD;
&#xD;
          -  Allergy to levetiracetam.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maryam Rahman, MS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 6, 2015</study_first_submitted>
  <study_first_submitted_qc>January 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2015</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levetiracetam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>October 5, 2021</submitted>
    <returned>November 2, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

